• An evaluation of general safety will be undertaken: · Number of systemic clinical and biological adverse events occurring during the study. · Number of patients who prematurely discontinued study treatment for reasons linked to the general safety. [ Time Frame: 58 days post infusion of allogeneic NK-cells ] [ Designated as safety issue: Yes ]
  

• Duration of donow NK cells in the recipient's blood [ Time Frame: 58 days post infusion of allogeneic NK-cells ] [ Designated as safety issue: Yes ]
  
• Patient survival at 100 days and at one year post treatment (all cause mortality) [ Time Frame: 100 days and one year post treatment ] [ Designated as safety issue: Yes ]
  
• Occurrence of new cancer during the first year post infusion of allogeneic NK-cells [ Time Frame: One year post infusion of allogeneic NK-cells ] [ Designated as safety issue: Yes ]
  
• Documented systemic infections during the first 30 days post infusion of allogeneic NK-cells. [ Time Frame: 30 days post infusion of allogeneic NK-cells ] [ Designated as safety issue: Yes ]
  
• Occurrence of other possible NK-infusions related complications such as,fever, capillary leak syndrome and/or allergic reaction. [ Time Frame: 58 days post infusion of allogeneic NK-cells ] [ Designated as safety issue: Yes ]
  

Natural killer cells are blood cells that are responsible for eliminating cancer cells especially when there are only a few. It has been shown that NK cells coming from a "mismatched" person (a relative) have a better chance than the patient's own NK cells to recognize and kill cancer cells. These cells will be collected from the blood of a parent, child or sibling and after preparation in the laboratory, will be given to the patient early after an autologous stem cell transplantation like a blood or platelet transfusion. A person who has been diagnosed with a blood tumor and received an autologous stem cell transplant has the chance of his/her cancer coming back. This study uses NK cells obtained from a relative to prevent disease recurrence by potentially eliminating and eradicating any residual cancerous cells.

Inclusion Criteria:

• Patients who have undergone an autologous stem cell transplant for the following diseases:

  • Acute Myeloid Leukemia
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Disease
  • Multiple Myeloma
• Age 13 - 70 years old
• Able to give informed consent
• Hepatic and renal function: bilirubin less than or equal to 2x normal limits, AST and ALT less than or equal to 2x normal limits, serum creatinine less than or equal to 1.5x normal
• ECOG Performance Status less than or equal to 1 (at planned time of transplantation)
• Patients with no active infection

Exclusion Criteria:

• Patients who have not recovered sufficiently from the side effects of the autologous transplant (i.e. have > grade 2 toxicity in any organ system)
• Patients who have insufficient engraftment parameters according to the following criteria: WBC < 2,500 /mm3 and platelets < 50,000/mm3
• Radiation therapy, chemotherapy, or immunotherapy beginning one week before NK-cell infusion and lasting 2 weeks after NK-cell infusion.
• Intrinsic impaired organ function (as stated above).
• Physical or psychiatric conditions that in the estimation of the PI or designee place the patient at high-risk of toxicity or non-compliance.
• Uncontrolled, life-threatening infections at the time of infusion.
• Concurrent treatment with corticosteroids and/or other immuno-suppressive drugs.